ANI Pharmaceuticals (NASDAQ:ANIP) was upgraded by research analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued to investors on Thursday.
Other equities research analysts have also recently issued reports about the company. ValuEngine cut ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, April 2nd. TheStreet cut ANI Pharmaceuticals from a “b” rating to a “c+” rating in a research note on Tuesday, February 20th. Zacks Investment Research cut ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, January 2nd. Finally, Canaccord Genuity set a $77.00 price objective on ANI Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, December 29th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $72.25.
Shares of ANI Pharmaceuticals stock opened at $59.52 on Thursday. The company has a quick ratio of 2.39, a current ratio of 3.36 and a debt-to-equity ratio of 1.13. ANI Pharmaceuticals has a 12 month low of $42.23 and a 12 month high of $74.70. The firm has a market cap of $709.53, a P/E ratio of 17.14 and a beta of 2.91.
ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Tuesday, February 27th. The specialty pharmaceutical company reported $1.08 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.06. ANI Pharmaceuticals had a positive return on equity of 23.41% and a negative net margin of 0.61%. The business had revenue of $47.30 million during the quarter, compared to analysts’ expectations of $52.55 million. During the same period in the previous year, the firm earned $0.84 earnings per share. The firm’s quarterly revenue was up 23.8% compared to the same quarter last year. equities research analysts anticipate that ANI Pharmaceuticals will post 5.17 earnings per share for the current fiscal year.
In other ANI Pharmaceuticals news, SVP James G. Marken sold 4,177 shares of the business’s stock in a transaction dated Monday, March 5th. The stock was sold at an average price of $61.92, for a total value of $258,639.84. Following the completion of the transaction, the senior vice president now directly owns 66,439 shares of the company’s stock, valued at $4,113,902.88. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Daniel Raynor sold 7,215 shares of the business’s stock in a transaction dated Monday, March 19th. The shares were sold at an average price of $60.85, for a total value of $439,032.75. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 187,620 shares of company stock valued at $11,696,748. 31.80% of the stock is owned by insiders.
A number of large investors have recently bought and sold shares of ANIP. Bank of Montreal Can grew its stake in ANI Pharmaceuticals by 681.8% in the fourth quarter. Bank of Montreal Can now owns 2,408 shares of the specialty pharmaceutical company’s stock valued at $156,000 after acquiring an additional 2,100 shares during the period. SG Americas Securities LLC acquired a new position in ANI Pharmaceuticals in the third quarter valued at about $197,000. Millennium Management LLC acquired a new position in ANI Pharmaceuticals in the fourth quarter valued at about $210,000. Driehaus Capital Management LLC acquired a new position in ANI Pharmaceuticals in the fourth quarter valued at about $220,000. Finally, BNP Paribas Arbitrage SA grew its stake in ANI Pharmaceuticals by 106.5% in the third quarter. BNP Paribas Arbitrage SA now owns 4,443 shares of the specialty pharmaceutical company’s stock valued at $233,000 after acquiring an additional 2,291 shares during the period. 56.06% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This news story was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/14/ani-pharmaceuticals-anip-rating-increased-to-hold-at-bidaskclub.html.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.